

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/607,051	06/26/2003	Duane A. Burnett	CN01594K	4136
24265	7590 06/03/2004		EXAM	INER
SCHERING-PLOUGH CORPORATION			DESAI, RITA J	
	PATENT DEPARTMENT (K-6-1, 1990) 2000 GALLOPING HILL ROAD			PAPER NUMBER
	TH, NJ 07033-0530		1625	

DATE MAILED: 06/03/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/607,051	BURNETT ET AL.				
Office Action Summary	Examiner	Art Unit				
	Rita J. Desai	1625				
The MAILING DATE of this communication ap	opears on the cover sheet	with the correspondence address				
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a re - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the maili earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on	136(a). In no event, however, may ply within the statutory minimum of d will apply and will expire SIX (6) N tte, cause the application to become ing date of this communication, eve	a reply be timely filed hirty (30) days will be considered timely. ONTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).				
2a) This action is FINAL . 2b) ⊠ This action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) 1-26 is/are pending in the application 4a) Of the above claim(s) is/are withdr 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-26 are subject to restriction and/or Application Papers 9) The specification is objected to by the Examin	awn from consideration. r election requirement.					
	10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the I	e drawing(s) be held in abe ection is required if the draw	yance. See 37 CFR 1.85(a). ing(s) is objected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority docume application from the International Bure * See the attached detailed Office action for a list	nts have been received. nts have been received i iority documents have be eau (PCT Rule 17.2(a)).	n Application No en received in this National Stage				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date	Paper	w Summary (PTO-413) No(s)/Mail Date of Informal Patent Application (PTO-152)				

Art Unit: 1625

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claim s 16, 1-15, 17, 20 in part, drawn to compounds and pharmaceutical compositions, wherein n=0, r=1, Ar is aryl, R4 is an aryl and Y is (CR2R3)p CO-NH, R1 is as given in the compounds of claim 16, classified in class 546, 514, subclass 18, 278.
- II. Claims 1-15, 17, 20 drawn to compounds and pharmaceutical compositions wherein n, r, Ar, Y and R1 are different from the group I, classified in various classes and subclasses. A further election of a single disclosed species is required. May be subject to further restriction.
- III. Claim18, 19, 21, 22-26, drawn to various methods of treating, classified in class514 and various subclasses. This group if elected may be subject to restriction.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have a different core. Even the spiro rings are not the common core. Thus these groups have a different bonding and have different modes of operation. Applicants compounds are pharmaceuticals and compounds act on certain receptor cites in a lock and key mechanism and hence the structure and bonding is a critical aspect of the invention. Thus the inventions are unrelated.

Art Unit: 1625

Inventions I, II and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case there are numerous drugs which are on the market to treat obesity, diabetes and such the process of using the product as claimed can be practiced by another product.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Group II or III, restriction for examination purposes as indicated is proper.

A telephone call was made to Mr. William Lee on 5/27/2004 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

Art Unit: 1625

currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Applicants preserve their right to file a divisional on the canceled non-elected claims without prejudice, in due course.

Rejoinder:-

If applicants elect Group I or II and if it is found to be allowable then ONE method of treating, limited to the same scope of the compounds will be rejoined with the compound claims.

If applicant 's traverse on the grounds that the inventions are not patentably distinct, applicants should submit evidence or identify such evidence now of record showing the groups to be obvious variants or clearly admit on the record that this is the case. In either instance if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 USC 103 of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rita J. Desai whose telephone number is 571-272-0684. The examiner can normally be reached on Monday - Friday,9:30 am to 6:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on 571-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1625

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

R.D. June 1st 2004. Rita J. Desai
Primary Examiner
Art Unit 1625